Our team
Experienced leaders dedicated to excellence
Curt LaBelle
With a 20 year commitment to advancing healthcare through strategic investments, Curt is the Founder & Chair of Global Health Funds, managing the private investments of the $300M AXA Prime Fund.
Throughout his career, Curt has played pivotal roles on the boards of numerous influential healthcare companies. His board and observer positions have included KAI Pharmaceuticals (acquired by Amgen), Sirion Therapeutics (acquired by Bausch & Lomb and Alcon), Impulse Monitoring (acquired by NuVasive), TransMolecular (acquired by Morphotek), Estech (acquired by AtriCure), Coherex (acquired by Johnson & Johnson), Exagen Diagnostics, SafeOp, and several others.
Previously, Curt served as the managing partner of the $108M Global Health Investment Fund, held the position of managing director at Tullis Health Investors and served as a vice president at Investor Growth Capital.
Mark Sullivan
With over 30 years of pharmaceutical development experience at renowned organisations such as GSK in London and Gilead Sciences in San Francisco, Mark has significantly contributed to the field of global health. In 2005, he founded Medicines Development for Global Health, and in 2020, he established Atticus Medical.
Throughout his career, Mark has worked on over 40 drug development programs, successfully taking four drugs to FDA approval. Notably, he led the FDA regulatory approval for moxidectin, marking the first new treatment for river blindness in more than 20 years.
In recognition of his contributions, Mark was honoured as VIC Australian of the Year in 2019 and an Officer of the Order of Australia in 2023. He serves as an Adjunct Professor at the Kirby Institute, UNSW, and advises both Adjuvant Capital in New York and the AXA Prime Fund in London.
John Lambert
John began his career as an organic chemist, studying at the University of Melbourne, ANU, and Harvard University before spending about seven years in academic research and teaching at The University of Melbourne. With now over 20 years of experience in pharmaceutical development, he has held various leadership roles throughout his career.
John has served as a leader at Biota Pharmaceuticals and as CEO of the ASX-listed Amplia Therapeutics. He also held a significant position as a Senior Director at Medicines Development for Global Health, where he was part of the team that achieved FDA approval in 2018 for moxidectin, a new treatment for river blindness.
Hamish George
Hamish is a Director at Bio101 Financial Advisory (‘Bio101’), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits.
He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.